HIV PReP Health

Injectable PrEP receives ‘breakthrough therapy’ designation from FDA

Reading now: 601
metroweekly.com

Truvada.But earlier this year GlaxoSmithKline announced that injections of the antiretroviral cabotegravir, administered every two months, were more effective at preventing transmission of HIV than Truvada.Read More: PrEP injection every two months proves more effective than daily TruvadaTruvada is already up to 99% effective at preventing transmission of the virus, but GSK’s injections were found to be even more effective — 69% more — so much so that clinical trials were stopped early, and those who had been given Truvada were offered bimonthly injections instead.This week, ViiV Healthcare, which is owned by GSK and developed the injections, announced that the U.S.

Read more on metroweekly.com
The website celebsbar.com is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

DMCA